FCFS

160

+1.52%↑

RPT.US

2.49

-1.19%↓

FCFS

160

+1.52%↑

RPT.US

2.49

-1.19%↓

FCFS

160

+1.52%↑

RPT.US

2.49

-1.19%↓

FCFS

160

+1.52%↑

RPT.US

2.49

-1.19%↓

FCFS

160

+1.52%↑

RPT.US

2.49

-1.19%↓

Search

Bayer AG

Gesloten

SectorFinanciën

28.37 -4.94

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

28.285

Max

28.39

Belangrijke statistieken

By Trading Economics

Inkomsten

-1.5B

-190M

Verkoop

-3B

11B

EPS

1.23

Dividendrendement

0.42

Winstmarge

-1.769

Werknemers

89,556

EBITDA

-3.4B

236M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+0.74% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

0.42%

3.89%

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-545M

26B

Vorige openingsprijs

33.31

Vorige sluitingsprijs

28.37

Nieuwssentiment

By Acuity

29%

71%

76 / 528 Rangschikking in Finance

Technische score

By Trading Central

Vertrouwen

Bearish Evidence

Bayer AG Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

12 nov 2025, 07:32 UTC

Winsten

Bayer Posts Net Loss on Litigation Hit

6 aug 2025, 06:18 UTC

Winsten

Bayer Loss Widens on Litigation Charges

12 nov 2025, 11:15 UTC

Marktinformatie
Winsten

Bayer's Crop Science Unit Drives Strong Results -- Market Talk

12 nov 2025, 06:33 UTC

Winsten

Bayer Affirms Objective to Significantly Contain Litigation Risk by End of 2026

12 nov 2025, 06:31 UTC

Winsten

Analysts Had Seen Bayer 3Q Net Loss at EUR413M

12 nov 2025, 06:31 UTC

Winsten

Bayer 3Q Net Loss EUR963M

12 nov 2025, 06:30 UTC

Winsten

Analysts Had Seen Bayer 3Q EBITDA Before Special Items at EUR1.27B

12 nov 2025, 06:30 UTC

Winsten

Bayer 3Q EBITDA Before Special Items EUR1.51B

12 nov 2025, 06:30 UTC

Winsten

Analysts Had Seen Bayer 3Q Sales at EUR9.69B

12 nov 2025, 06:30 UTC

Winsten

Bayer 3Q Sales EUR9.66B

12 nov 2025, 06:30 UTC

Winsten

Bayer Backs 2025 View

6 aug 2025, 15:01 UTC

Marktinformatie
Winsten

Bayer Expects Bumper U.S. Crop -- Market Talk

6 aug 2025, 14:52 UTC

Marktinformatie

Bayer says Litigation Situation With Roundup 'Unsustainable' -- Market Talk

6 aug 2025, 09:05 UTC

Marktinformatie

Bayer Expects Weedkiller Dicamba Back on U.S. Market in 2026 -- Market Talk

6 aug 2025, 07:27 UTC

Marktinformatie
Winsten

Bayer's Results Deliver Few Surprises -- Market Talk

6 aug 2025, 05:43 UTC

Winsten

Bayer: Crop Science Division Now in a Position to Streamline Production and Operations

6 aug 2025, 05:43 UTC

Winsten

Bayer: Making Headway on Plan to Improve Profitability in Agricultural Business

6 aug 2025, 05:42 UTC

Winsten

Bayer Affirms Objective to Significantly Contain Litigation Risk by End of 2026

6 aug 2025, 05:41 UTC

Winsten

Bayer Expects Significant Currency Fluctuations With Headwinds on Sales and Profits, Favorable Effects on Debt

6 aug 2025, 05:41 UTC

Winsten

Bayer: 2H Will Be Marked by Progress on Strategic Priorities, Launches, Geopolitical and Currency Crosswinds

6 aug 2025, 05:33 UTC

Winsten

Bayer 2Q Net Loss EUR199M

6 aug 2025, 05:32 UTC

Winsten

Bayer Had Pre-Announced 2Q Ebitda Before Special Items at EUR2.1B

6 aug 2025, 05:32 UTC

Winsten

Bayer 2Q Ebitda Before Special Items EUR2.11B

6 aug 2025, 05:32 UTC

Winsten

Bayer Had Pre-Announced 2Q Sales at EUR10.7B

6 aug 2025, 05:32 UTC

Winsten

Bayer 2Q Sales EUR10.74B

30 jun 2025, 15:09 UTC

Marktinformatie

Supreme Court Asks for Government's View on Bayer's Roundup Case -- Market Talk

5 jun 2025, 08:29 UTC

Marktinformatie

Bayer Earnings Expectations Might Have Bottomed out -- Market Talk

30 mei 2025, 13:47 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Consumer Health Sector Has Room for More Dealmaking -- Market Talk

27 mei 2025, 12:22 UTC

Marktinformatie
Winsten

Bayer's Prospects Are Improving -- Market Talk

16 mei 2025, 13:42 UTC

Populaire aandelen

Stocks to Watch Friday: Charter, Novo Nordisk, Applied Materials -- WSJ

Peer Vergelijking

Prijswijziging

Bayer AG Prognose

Koersdoel

By TipRanks

0.74% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 28.61 EUR  0.74%

Hoogste 35 EUR

Laagste 23 EUR

Gebaseerd op 9 Wall Street-analisten die 12-maands prijsdoelen bieden voor Bayer AG - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

9 ratings

3

Buy

6

Hold

0

Sell

Technische score

By Trading Central

22.99 / 23.88Steun & Weerstand

Korte Termijn

Bearish Evidence

Gemiddeld Termijn

Bullish Evidence

Lange Termijn

Bullish Evidence

Sentiment

By Acuity

76 / 528 Rangschikking in Financiën

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Bayer AG

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment provides breeding, propagation, and production/processing of seeds, including seed dressing. It has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc.; strategic research partnership with University of Oxford to develop novel gynecological therapies; Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases; and collaboration and license agreement with Cytokinetics for the development and commercialization of aficamten. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. The company was founded in 1863 and is headquartered in Leverkusen, Germany.
help-icon Live chat